
Inhalers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Description
Inhalers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “Inhalers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Inhalers pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Inhaler devices deliver medication to the lungs.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Inhalers under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Inhalers and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Inhalers under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
185 Pages
- About GlobalData
- Inhalers Overview
- Inhalers - Pipeline Products by Stage of Development
- Inhalers - Pipeline Products by Segment
- Inhalers - Pipeline Products by Territory
- Inhalers - Pipeline Products by Regulatory Path
- Inhalers - Pipeline Products by Estimated Approval Date
- Inhalers - Ongoing Clinical Trials
- Inhalers Companies - Pipeline Products by Stage of Development
- Inhalers - Pipeline Products by Stage of Development
- 1nhaler Ltd Company Overview
- Acorda Therapeutics Inc Company Overview
- Advent Pharmaceuticals Pty Ltd Company Overview
- Aerami Therapeutics Holdings Inc Company Overview
- Aespira Ltd. Company Overview
- AKELA Pharma Inc. (Formerly LAB International, Inc.) (Inactive) Company Overview
- AsMedic Ltd. Company Overview
- Ayrton Saunders Ltd Company Overview
- Bayer AG Company Overview
- Belhaven Biopharma Inc Company Overview
- Bellerophon Therapeutics Inc Company Overview
- Cambridge Healthcare Innovations Ltd Company Overview
- Cipla Ltd Company Overview
- Covinhaler LLP Company Overview
- Creare LLC Company Overview
- De Motu Cordis Pty Ltd Company Overview
- DMK Pharmaceuticals Corp Company Overview
- Drexel University Company Overview
- Engage Therapeutics Inc Company Overview
- Findair Sp zoo Company Overview
- FocusStart LLC Company Overview
- Glenmark Pharmaceuticals Ltd Company Overview
- GSK plc Company Overview
- Hovione Technology Ltd Company Overview
- Iconovo AB Company Overview
- Lupin Pharmaceuticals Inc Company Overview
- MannKind Corp Company Overview
- Medihale Ltd (Inactive) Company Overview
- Monash University Company Overview
- Nektar Therapeutics Company Overview
- North Carolina State University Company Overview
- Novartis AG Company Overview
- Ology Bioservices Inc Company Overview
- OPKO Health Inc Company Overview
- OtiTopic Inc Company Overview
- Pai Life Sciences Inc Company Overview
- Phargentis SA Company Overview
- Pneuma Respiratory Inc Company Overview
- Pure Scientific Technologies Inc Company Overview
- PureIMS BV Company Overview
- Quench Medical Inc Company Overview
- Receptor Life Sciences Inc Company Overview
- Resolve Digital Health Inc Company Overview
- Respira Therapeutics Inc Company Overview
- Respirent Pharmaceuticals Co Ltd Company Overview
- Rhinomed Ltd Company Overview
- Sandoz International GmbH Company Overview
- Seng Vital International GmbH Company Overview
- Sheffield Hallam University Company Overview
- Shin Nippon Biomedical Laboratories Ltd Company Overview
- Sinsin Pharmaceutical Co Ltd Company Overview
- Softhale NV Company Overview
- Spyryx Biosciences Inc (Inactive) Company Overview
- Syntara Ltd Company Overview
- Teva Pharmaceutical Industries Ltd Company Overview
- Transpire Bio Inc Company Overview
- United Therapeutics Corp Company Overview
- University of Kansas Company Overview
- University of Sydney Company Overview
- University of Texas Medical Branch at Galveston Company Overview
- Uscom Ltd Company Overview
- Vectura Group Plc Company Overview
- Veoli Ltd Company Overview
- Verona Pharma Plc Company Overview
- Virginia Commonwealth University Company Overview
- Jun 01, 2024: Boehringer Ingelheim's COPD and Asthma Inhalers Are Now Available for $35 a Month for Eligible Patients
- May 24, 2024: Iconovo Publishes the Annual Report 2023
- May 15, 2024: Cipla UPS Investment in Point-Of-Care Testing Firm Achira Labs
- May 13, 2024: Novo Nordisk Plans Bond Sale to Fund Expansion
- May 09, 2024: Nektar Therapeutics Reports First Quarter 2024 Financial Results
- May 08, 2024: Teva Pharmaceutical Industries Reports Earnings Results for the First Quarter Ended March 31, 2024
- May 06, 2024: Iconovo Receives Patent Protection for Icores in China
- May 02, 2024: Novo Nordisk's Sales Increased by 22% in Danish kroner and by 24% at Constant Exchange Rates to DKK 65.3 billion in the First Three Months of 2024
- May 01, 2024: MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
- Apr 30, 2024: 3M First-Quarter Results Driven by Strong Operational Performance; Company Initiates Full-Year 2024 Guidance Reflecting Completion of Solventum Spin
- Apr 16, 2024: Iconovo’s partner Monash University has completed enrollment in a Phase I clinical trial of inhaled oxytocin in ICOone
- Apr 11, 2024: Orion publishes Interim Report for January–March 2024 and Holds a Webcast on 25 April 2024
- Apr 09, 2024: Swiss Pharma Company Novartis to Lay Off 680 Employees from Switzerland and USA Offices in Next 2-3 Years
- Apr 03, 2024: Adherium Partners with Rimidi to Revolutionise Respiratory Clinical Management Solutions
- Mar 18, 2024: Astrazeneca Caps Patient Out-Of-Pocket Costs at $35 per Month for its US Inhaled Respiratory Portfolio
- Mar 15, 2024: Cipla Announces Appointment of Senior Management
- Mar 13, 2024: 3M Names New CEO Amid PFAS Battles, Health Spinoff
- Mar 12, 2024: 3M Announces New Leadership Appointments
- Mar 11, 2024: Iconovo to Present Positive Data From a Feasibility Study on Nanofitins in ICOone
- Mar 05, 2024: United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024
- Mar 04, 2024: Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
- Feb 27, 2024: MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
- Feb 20, 2024: MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
- Feb 08, 2024: Belhaven Biopharma Announces Groundbreaking Clinical Results for Nasdepi, the Revolutionary Nasal Dry Powder Epinephrine Product
- Feb 07, 2024: Iconovo Signs Additional Contract with Kiox Pharma for Development of a New Inhalable Treatment for Interstitial Lung Disease
- Feb 06, 2024: Iconovo Launches Improved Versions of Nasal Icoone Inhalers
- Feb 01, 2024: Qualcomm Reports Q1 Fiscal 2024 Results
- Feb 01, 2024: Iconovo Receives Order From Top-10 Pharma Company for Evaluation of Multi-Dose Inhaler
- Jan 31, 2024: Savara to Present at Two Upcoming Healthcare Conferences
- Jan 31, 2024: Kindeva Drug Delivery Launches New Analytical Services Global Business Unit
- Jan 31, 2024: Kindeva Drug Delivery Launches New Analytical Services Global Business Unit
- Jan 23, 2024: Orion Group Announces Executive Management Board
- Jan 23, 2024: 3M Delivers Strong Fourth-Quarter Results; Improves Operational Performance and Exceeds Earnings and Cash Flow Expectations
- Jan 16, 2024: 3M Picks Former NuVasive CEO as President of Medical Solutions
- Jan 15, 2024: Hassan Fahmi Appointed as Managing Director of GSK Egypt
- Jan 08, 2024: Iconovo Recruits Gary Pitcairn PhD as Senior Scientific Advisor
- Dec 04, 2023: Adherium Commences Production and US Market Release of Advanced Teva pMDI Compatible Smartinhaler
- Dec 04, 2023: Aptar Awarded US FDA Contract to Study Opportunities for Low Global Warming Potential Propellants for Metered Dose Inhalers
- Nov 09, 2023: 3M Announces Leadership Changes
- Nov 07, 2023: Tom Sweet Elected to 3M Board of Directors
- Nov 07, 2023: Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
- Nov 06, 2023: Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA
- Nov 02, 2023: Qualcomm Reports Q4 and Fiscal 2023 Results
- Oct 31, 2023: United Therapeutics Announces First Patient Enrolled in Phase 3 TETON PPF Study of Nebulized Tyvaso in Patients with Progressive Pulmonary Fibrosis
- Oct 27, 2023: Cipla Announces Unaudited Consolidated Financial Results for Quarter Ended September 30th, 2023
- Oct 24, 2023: 3M Reports Third Quarter 2023 Results; Company Increases Full Year Adjusted Earnings and Cash Flow Expectations
- Oct 19, 2023: DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth
- Oct 16, 2023: Orion publishes Interim Report for January–September 2023 on Thursday 26 October 2023
- Oct 15, 2023: Qualcomm To Layoff 1,258 Employees In Two Locations, Experts State That U.S. Efforts To Suppress China Backfired And Is Affecting Firms
- Oct 13, 2023: Qualcomm to Lay Off 1,258 Employees in California
- Oct 12, 2023: Qualcomm to Cut Roughly 1258 Jobs in California
- Oct 03, 2023: Nemera reinforces commitment to sustainability with first integrated ESG report
- Sep 28, 2023: Teva Announces Changes to Executive Management Team
- Sep 25, 2023: Nemera Announces Commitment to sustainability
- Sep 10, 2023: Nemera extends manufacturing capabilities in North America
- Sep 05, 2023: MannKind Announces Participation at Upcoming Conferences
- Aug 28, 2023: Novartis to Let Go 100 Employees in Latest Round of Layoffs
- Aug 23, 2023: 3M Appoints Carrie Cox as Chairman of the Board of Directors of the Independent Health Care Company
- Aug 22, 2023: Bryan Hanson Named CEO of 3M's Health Care Business Group
- Aug 18, 2023: Qualcomm to Reportedly Cut 200 Jobs in Taiwan
- Aug 17, 2023: Iconovo Receives Additional Development Contract From Kiox Pharma For New Inhalable Treatment Against Rare Disease
- Aug 17, 2023: Ziccum to present at Investor Conference BioFuture 2023 in New York
- Aug 11, 2023: Audrey Choi elected to 3M Board of Directors
- Aug 03, 2023: Qualcomm Announces Third Quarter Fiscal 2023 Results
- Aug 01, 2023: MannKind Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
- Jul 31, 2023: Viatris Announces Launch of Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
- Jul 31, 2023: MannKind to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
- Jul 25, 2023: 3M Reports Second Quarter 2023 Results; Proactive Initiatives Drive Strong Quarterly Financial Results; Raises Full-Year Adjusted EPS Guidance
- Jul 21, 2023: Teva UK Launches New Goresp Digihaler System in UK
- Jul 20, 2023: Command Brand Announces Bobby Berk as First-Ever Director of Dorm Design
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.